JP2025503594A5 - - Google Patents

Info

Publication number
JP2025503594A5
JP2025503594A5 JP2024540758A JP2024540758A JP2025503594A5 JP 2025503594 A5 JP2025503594 A5 JP 2025503594A5 JP 2024540758 A JP2024540758 A JP 2024540758A JP 2024540758 A JP2024540758 A JP 2024540758A JP 2025503594 A5 JP2025503594 A5 JP 2025503594A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
rna
leukemia
crispr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024540758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503594A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/060230 external-priority patent/WO2023133505A2/en
Publication of JP2025503594A publication Critical patent/JP2025503594A/ja
Publication of JP2025503594A5 publication Critical patent/JP2025503594A5/ja
Pending legal-status Critical Current

Links

JP2024540758A 2022-01-07 2023-01-06 白血病および骨髄異形成を治療するためのキヌレニン合成および／またはシグナル伝達の阻害 Pending JP2025503594A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263297390P 2022-01-07 2022-01-07
US63/297,390 2022-01-07
PCT/US2023/060230 WO2023133505A2 (en) 2022-01-07 2023-01-06 Inhibition of kynurenine synthesis and/or signaling to treat leukemia and myelodysplasia

Publications (2)

Publication Number Publication Date
JP2025503594A JP2025503594A (ja) 2025-02-04
JP2025503594A5 true JP2025503594A5 (https=) 2025-12-19

Family

ID=87074305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024540758A Pending JP2025503594A (ja) 2022-01-07 2023-01-06 白血病および骨髄異形成を治療するためのキヌレニン合成および／またはシグナル伝達の阻害

Country Status (5)

Country Link
US (1) US20240350669A1 (https=)
EP (1) EP4460585A4 (https=)
JP (1) JP2025503594A (https=)
CA (1) CA3246102A1 (https=)
WO (1) WO2023133505A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025038794A1 (en) * 2023-08-15 2025-02-20 The Trustees Of Columbia University In The City Of New York Antibodies targeting serum amyloid a (saa) and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201414730D0 (en) * 2014-08-19 2014-10-01 Tpp Global Dev Ltd Pharmaceutical compound
WO2016201354A1 (en) * 2015-06-11 2016-12-15 Globavir Biosciences, Inc. Methods and compositions for treating cancer
CN114989205A (zh) * 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
ES2973832T3 (es) * 2019-10-18 2024-06-24 Forty Seven Inc Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda

Similar Documents

Publication Publication Date Title
Nicoloso et al. MicroRNAs—the micro steering wheel of tumour metastases
ES2610568T3 (es) Inducción de omisión de exones en células eucarióticas
JP2022078069A (ja) 二本鎖ＲＮＡによるα－１アンチトリプシンの特異的阻害のための方法及び組成物
CN107177598B (zh) 用于抑制BIRC5靶基因mRNA表达的寡核酸分子及其成套组合物
JP2018513668A5 (https=)
CN102341498A (zh) 通过抑制血管内皮生长因子(vegf)的天然反义转录子治疗vegf相关的疾病
JP2015518714A5 (https=)
JP2008283975A5 (https=)
JP2022511550A5 (https=)
Hu et al. Allele-selective inhibition of mutant atrophin-1 expression by duplex and single-stranded RNAs
CN116121246A (zh) 一种新型小激活rna
JP7191690B2 (ja) Ｂ型肝炎ウイルス（ｈｂｖ）感染を治療するための試薬及びその使用
JP2022500070A (ja) プログラム可能なｓｉＲＮＡ及びその使用
JP2025503594A5 (https=)
JP2025148338A (ja) Ｒｎａ治療薬及びその使用方法
CN115916978A (zh) 寡核苷酸
JP7610195B2 (ja) Ｔｕｔ４／７発現調節因子を含む癌予防又は治療用薬学的組成物
JP2019525903A5 (https=)
JP2019513395A5 (https=)
RU2018138271A (ru) Реагенты для лечения окулофарингеальной мышечной дистрофии (OPMD) и их применение
CN108245527B (zh) 通过miR-1181进行抗癌的方法和药物及其应用
WO2025002247A1 (zh) 靶向人血管生成素样蛋白3的核酸及其用途
JP2018520150A5 (https=)
US20160272977A1 (en) DNMT Inhibitors
JPWO2023013613A5 (https=)